Photon Counting Computed Tomography in Heart Failure Patients

ConditionHeart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversità Vita-Salute San Raffaele

About this trial

Patients with severe acute or chronic heart failure are increasing worldwide. Heart failure clinicians are faced daily with the need to set up short- and long- term therapeutic strategies in line with heart failure etiology and myocardial recovery chances of each patient. Current treatment strategies for severe heart failure also include mechanical circulatory support with artificial devices (such as intraaortic balloon pump, Impella, ECMO, durable left ventricular assist device), which poses specific challenges for cardiac imaging. Through its ability to directly visualize scar and evaluate its transmural extent, cardiac magnetic resonance (CMR) offers a unique advantage over other currently available imaging techniques as a central player in viability assessment in patients with coronary disease, and represents the first line technique to investigate the chances of myocardial function recovery. CMR is also an important tool to provide diagnostic data in patients with non-ischemic heart failure. Unfortunately, CMR is not feasible in many heart failure patients (for example those on MCS therapy) due to the metallic components of the mechanical devices. In these patients, the computed tomography (CT) is the alternative imaging technique to visualize cardiac structures, diagnose complications, and assess possible indications for surgical interventions. However, CT has poorer resolution and do not offer the possibility to evaluate myocardial viability in patients with contraindication to CMR. Therefore, this issue currently represents one of the major unmet needs in the clinical management of severe heart failure patients.

Recent technological advances in the field of CT imaging have nevertheless paved the way to explore new pathways of myocardial viability assessment even in patients traditionally deemed unsuitable for CMR. The introduction of photon-counting detectors, in particular, is expected to be the next major breakthrough in clinical x-ray computed tomography (CT). Photon-counting detector (PCD)-CT will overcome several shortcomings and limitations of current CT systems: it might substantially improve and expand the applicability of CT imaging by offering intrinsic spectral capabilities, increased spatial resolution, reduced electronic noise and improved image contrast. On the basis of this physical principle PCCT has the promise to improve the actual not fully satisfactory quality of scar visualization in CT images. In particular, conventional scanners are affected by a limited contrast resolution which lead to a variable and relevant rate of false negative myocardial scar-free images depending on the assessor expertise. The constant improving of CT diagnostic field have been revolutionizing the diagnostic workflow in several cardiac disease. Late contrast enhancement CT demonstrated an adequate accuracy to detect and discriminate the etiology of both ischemic and non-ischemic causes of myocardial injury compared to actual gold standard exams in patients with a troponin-positive acute chest pain syndrome. The same technique showed good sensitivity, specificity and a high negative predictive value (95%) for the identification of myocardial scars imputed to be an anatomical substrate of ventricular tachycardia with a proper concordance with electro-anatomic mapping findings (k=0.536). Finally, this enormous potential of CT implementation with the novel PCCT will provide not only the possibility to further study myocardial viability, but also is expected to be superior to standard CT exams in details definition, reduction of electronic noise and increase of spatial resolution, with consequent specific advantages in patients with heart failure, especially those with artificial devices with metallic components, in which adverse event identification and definition (such as inflow or outflow thrombosis) is complex. Thanks to these multiple diagnostic and therapeutic advantages, in combination with the availability of the PCCT device, the use of such technique is now the preferred cardiac imaging examination for the study of cardiac anatomy and function in patients with severe heart failure and a contraindication to perform the gold standard CMR. Thus, we planned a single-center observational study to asses the performance of PCCT in the identification of myocardial scars and patterns in critically ill patients with severe heart failure.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Presence of acute or chronic heart failure

Clinical need for a CT exam with angiographic evaluation and scar imaging

Contraindication to perform a Magnetic Resonance Imaging.

All ages

Disqualifiers

Absence of acute or chronic heart failure

Absence of clinical indication to a CT exam

Contraindication to perform a CT exam.

Pregnancy

Trial population

All patients with acute or chronic heart failure undergoing PCCT will be included in the study, upon signature of informed consent.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Number of patients with myocardial late contrast enhancement (LCE) areas

Time frame
periprocedural
2

Identification of myocardial LCE patterns

LCE patterns: endocardial, mesocardial, epicardial, transmural.

Time frame
periprocedural
3

Quantification of myocardial extracellular volume (ECV) fraction.

Percentage of ECV

Time frame
periprocedural
4

The potential of PCCT in defining the etiology of heart failure

Identification of correlation of tissue features at imaging with different diseases causing heart failure

Time frame
periprocedural

Secondary outcomes

1

Number of patients with a PCCT detected source of infection

Time frame
periprocedural
2

Number of patients with a PCCT detected MCS device thrombosis

Time frame
periprocedural

Other outcomes

1

Residual left ventricle ejection fraction

Time frame
periprocedural

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Università Vita-Salute San Raffaele

Lead sponsor

Dr Anna Mara Scandroglio

Collaborator

Prof Antonio Esposito

Collaborator

Prof Anna Palmisano

Collaborator

This trial is not recruiting at the moment. You can still explore other options: